Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Regulation of B-CLL Survival (CD74 and CD84 as Regulators in Tumour Cells) for the Treatment of B Cell-Related Cancer
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1441
Chronic lymphocytic leukaemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Chronic lymphocytic leukaemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukaemia in adults, accounting for about 7,000 new cases of leukaemia each year. Presently, there is no cure for CLL, and the overall goal of leukaemia treatment is to bring about a remission.

Aims/Hypothesis

Therefore, identifying new proteins that may serve as a target for inducing cell death in the malignant cells is highly desirable.

Research

The present technology identifies a new regulator protein that is essential for the survival of CLL cells. B cells taken from CLL patients have a high level of the protein CD84. Stimulation of CD84 upregulates the survival of B-CLL. However, inhibition of CD84 activity with a blocking antibody downregulates the expression of another protein which controls B-CLL survival, thus inducing cell death. Therefore, the present invention reveals CD84 as a regulator of B-CLL survival

Conclusion

We have elucidated a new protein as a target to treat B cell-related cancer.

Relevance/Opportunity

Treatment of CLL, as well as other B cell-related cancers (eg, gastric cancer and renal cell carcinoma), by blocking CD84 activity. Please enquire regarding licensing or codevelopment partnerships quoting reference no. 1441.
FEATURED
Last Updated May 2015
Technology Type MECHANISM
Phase of Development PRECLINICAL
CORPORATION